Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Financing › Details

Eurazeo–SEVERAL: investment, 202203 first closing €160m of Kurma Partners Growth Opportunities Fund targeting €250m

 

Period Period 2022-03-07
Organisations Money taker Kurma Partners Growth Opportunities Fund
  Money source SEVERAL
Products Product Kurma Partners Growth Opportunities Fund
  Product 2 BIOTECH
     

Kurma Partners. (3/7/22). "Press Release: Kurma Partners Targets €250 Million for its First Growth Opportunities Fund". Paris.

Kurma Partners announced the first closing of its Growth Opportunities fund at €160 million. Meeting the demand of the growing maturity of the European biotech and healthtech ecosystem, this new fund, which is targeting €250 million, aims to accelerate the growth of the best European companies in the healthcare sector. For this fund, Kurma Partners has received the support of the European Investment Fund (EIF), Bpifrance1, the Belgian Growth Fund managed by PMV and BNP Paribas Fortis Private Equity, SFPI, BNP Paribas Fortis and Groupe Pasteur Mutualité. Eurazeo, which recently increased its stake in Kurma Partners, is also an anchor investor in this fund.

With this new fund, Kurma Partners now covers the entire financing spectrum, from company creation to the most advanced phases of development, in the biotech and healthtech sectors in which its teams have recognized expertise. The fund will mainly target unlisted European companies, addressing strong medical needs, in transformation from R&D-stage to being a commercial-stage company. In launching this Growth Fund, Kurma Partners is leveraging the convergence of scientific and sectoral expertise, entrepreneurial know-how and financial capacity. The objective is to invest in around 15 companies.

Rémi Droller and Vanessa Malier, Managing Partners of Kurma Partners commented "The number of European biotech and healthtech companies with products in the final stages of development has been surging in recent years. The launch of the Growth activity will allow us to support the maturity of the European market and to be up to the challenges of companies at the time of their industrial and commercial scale up".

The fund has been granted with the Tibi label making it eligible for the €6 billion mobilized by French institutional investors to accelerate the growth of innovative companies and turn them into national leaders with global ambitions. To structure the fund and support its growth, Kurma recently strengthened its dedicated team, already composed of Rémi Droller and Vanessa Malier, by welcoming Jean-François Rivassou and Daniel Parera as Partners to operate respectively from its Paris and Munich offices.

The fund will benefit from the expertise of the whole team and in particular that of Philippe Peltier, Managing Partner in charge of early stage healthtech at Kurma, who will join its investment committee.

In addition, Tony Rosenberg, former Novartis Corporate Head of M&A and Licensing and member of the Executive Committee of Novartis Pharma, and Philippe Gallone, Managing Director of Moelis & Company, will join Kurma as Senior Advisors.


1 Bpifrance invests in equity, through the Growth Fund of Funds on behalf of private insurers and La Caisse des Dépôts, and through the Biotech Health Acceleration Fund (FABS), managed on behalf of the State by Bpifrance, as part of the France 2030 plan.


Press contact

Oxygen PR Agency
Emeline Ouedy | emeline.o@oxygen-rp.com | +33 6 89 52 78 39
Sandra Codognotto | sandra.c@oxygen-rp.com | +33 6 63 92 36 00

   
Record changed: 2024-01-09

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Eurazeo (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top